Companies and Markets
Call us on +44 (0) 203 086 8600
Market Research A to Z | Company Profiles A to Z | RegisterRegister | Contact UsContact Us | Shopping Basket Shopping Basket
+44 (0) 203 086 8600 Call us on

Salix Pharmaceuticals, Ltd. - SWOT Analysis

77.69

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£77.69

Change Currency

GBP EURO USD
GBP EURO USD

Market

Healthcare and Medical

Report Type

Company Profile

Country

Global

Published

14 September 2010

Number of Pages

24

Report Delivery

Email

Delivery Lead Time

-

Publisher

Datamonitor

File Format

-

Salix Pharmaceuticals, Ltd. - SWOT Analysis company profile is the essential source for top-level company data and information. Salix Pharmaceuticals, Ltd. - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Salix Pharmaceuticals (Salix) is a specialty pharmaceutical company that develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The company's marketed drugs for gastrointestinal disease includes XIFAXAN (rifaximin) tablets 200 mg, OSMOPREP (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, and METOZOLV ODT (metoclopramide HCl). It primarily operates in the US. The company is headquartered in Morrisville, North Carolina and employed 395 people as of December 2009. The company recorded revenues of $232.9 million during the financial year (FY) ended December 2009, an increase of 30.3% over FY2008. The increase in revenues was due to higher sales of XIFAXAN, MOVIPREP and APRISO. The operating loss of the company was $40.1 million during FY2009, as compared to the operating loss of $46.7 million in FY2008. The net loss of the company was $43.6 million in FY2009, as compared to the net loss of $ 47.6 million in FY2008.

Scope of the Report

- Provides all the crucial information on Salix Pharmaceuticals, Ltd. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting Salix Pharmaceuticals, Ltd. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Salix Pharmaceuticals, Ltd.
-Data is supplemented with details on Salix Pharmaceuticals, Ltd. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Salix Pharmaceuticals, Ltd.

Reasons to Purchase

- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£77.69

Change Currency

GBP EURO USD

Change Currency

GBP
USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings